FUSN on NASDAQ

Fusion Pharmaceuticals

Logo: fusionpharma.com3

In its 2024 annual report the company says: “We are a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. We have developed our Targeted Alpha Therapies, or TAT, platform to enable us to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha particle payloads to tumors.”6 It is headquartered in Hamilton, Canada.1 Its shares trade on NASDAQ under the symbol FUSN.1

Price unavailable

Last updated Oct 20, 2026.

Overview

Compare with Humacyte, Inc., Aligos Therapeutics, Inc. or Proteon Therapeutics, or pick any stock.

  • TickerFUSN on NASDAQ1
  • Industrypharmaceutical industry1
  • HeadquartersHamilton, Canada1
  • Websitefusionpharma.com
  • Incorporated inCanada (Federal Level)4
  • Business address270 Longwood Road South, Hamilton, A6 L8P 0A64
  • Filer category, Emerging growth company4

See how the biggest companies compare on our leaderboards

We are a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. We have developed our Targeted Alpha Therapies, or TAT, platform to enable us to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha particle payloads to tumors. Our TAT platform is underpinned by our ability to radiolabel various classes of targeting molecules (including antibodies, small molecules and peptides), our research and insights into the underlying chemistry and biology of alpha emitting radiopharmaceuticals, our differentiated capabilities in target identification, candidate generation, manufacturing and supply chain, our proprietary Fast-Clear TM linker technology used in conjunction with antibody-based targeting molecules, and development of imaging agents. We believe that our TATs have the potential…6 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-4798.5%Operating margin7
-4588.8%Net margin7
41.5%Revenue growth, 20237
-42.7%Return on equity7
0.16×Debt to equity7
-$85.7MFree cash flow7

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development99¢$70.1M
  • Income tax1¢$787.0K

Out of $2.1M in revenue.7 The company lost money this year.

Financial statements

Revenue87$2.1M in 2023+44% since 2021
0$1.0M$2.0M$3.0M2021: $1.4M$1.4M20212022: $1.5M$1.5M2022+1%2023: $2.1M$2.1M2023+42%
Operating income91087-$99.2M in 2023+445% since 2019
-$100.0M-$75.0M-$50.0M-$25.0M02019: -$18.2M-$18.2M20192020: -$37.9M-$37.9M2020+108%2021: -$82.0M-$82.0M2021+116%2022: -$88.0M-$88.0M2022+7%2023: -$99.2M-$99.2M2023+13%
Net income91087-$94.9M in 2023+486% since 2019
-$100.0M-$75.0M-$50.0M-$25.0M02019: -$16.2M-$16.2M20192020: -$78.3M-$78.3M2020+384%2021: -$81.0M-$81.0M2021+3%2022: -$87.6M-$87.6M2022+8%2023: -$94.9M-$94.9M2023+8%
Fiscal year201820192020202120222023
Revenue$1.4M8$1.5M7$2.1M7
Research and development$10.6M9$17.2M10$56.4M8$58.9M7$70.1M7
Operating expenses$83.5M8$89.5M7$101.3M7
Operating income-$18.2M9-$37.9M10-$82.0M8-$88.0M7-$99.2M7
Income before tax-$81.2M8-$89.4M7-$94.1M7
Income tax$251.0K9$2.6M10-$118.0K8-$1.8M7$787.0K7
Net income-$16.2M9-$78.3M10-$81.0M8-$87.6M7-$94.9M7
Earnings per share-$1.908-$2.007-$1.457
Earnings per share (diluted)-$1.908-$2.007-$1.457
Shares (weighted, basic)42.6M shares843.7M shares765.6M shares7
Shares (weighted, diluted)42.6M shares843.7M shares765.6M shares7

Compare Fusion Pharmaceuticals with another company

Corporate structure

Fusion Pharmaceuticals sits at the top of its group. 2 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Fusion Pharmaceuticals

  • HealthCap VII, L.P. Filed SC 13D/A on Fusion Pharmaceuticals, latest Mar 20, 2024 (3 filings since Mar 6, 2023)
  • CANADA PENSION PLAN INVESTMENT BOARD Filed SC 13G/A on Fusion Pharmaceuticals, latest Feb 14, 2024
  • Avidity Partners Management LP Filed SC 13G/A on Fusion Pharmaceuticals, latest Feb 13, 2024 (2 filings since Oct 23, 2023)
  • FMR LLC Filed SC 13G/A on Fusion Pharmaceuticals, latest Feb 9, 2024 (3 filings since Feb 9, 2022)
  • PERCEPTIVE ADVISORS LLC Filed SC 13G on Fusion Pharmaceuticals, latest Jan 19, 2024
  • James E. Flynn Filed SC 13G on Fusion Pharmaceuticals, latest Dec 18, 2023
  • ORBIMED ADVISORS LLC Filed SC 13D/A on Fusion Pharmaceuticals, latest May 16, 2023 (2 filings since Feb 28, 2023)
  • ADAMS STREET PARTNERS LLC Filed SC 13G/A on Fusion Pharmaceuticals, latest Feb 14, 2022
  • TPG GP A, LLC Filed SC 13D/A on Fusion Pharmaceuticals, latest Jan 18, 2022
  • Fusion Pharmaceuticals Hamilton, Canada
    • Fusion Pharmaceuticals US Inc. Subsidiary · Delaware, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Fusion Pharmaceuticals reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$7.8M7 Dec 31, 2023$6.6M7 Dec 31, 2022+17.3%
Accumulated depreciation$2.5M7 Dec 31, 2023$2.0M7 Dec 31, 2022+23.9%
Property and equipment, net$5.3M7 Dec 31, 2023$4.6M7 Dec 31, 2022+14.5%
Operating-lease assets (leased space)$18.6M7 Dec 31, 2023$5.7M7 Dec 31, 2022+227.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$61.5M7 Dec 31, 2023$43.9M7 Dec 31, 2022+40.1%
Marketable securities, current$172.2M7 Dec 31, 2023$127.0M7 Dec 31, 2022+35.5%
Marketable securities, non-current$13.7M7 Dec 31, 2023$15.8M7 Dec 31, 2022−12.9%
Debt securities available for sale$185.9M7 Dec 31, 2023$142.8M7 Dec 31, 2022+30.2%
Long-term investments$13.7M7 Dec 31, 2023$15.8M7 Dec 31, 2022−12.9%

Leadership

Who has led Fusion Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. John Valliant2020–2024

President

  1. Mohit Rawat2021–2024

Chief financial officer

  1. John J. Crowley2020–2024
2025
Board members and other officers (14)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Fusion Pharmaceuticals US Inc. Delaware5

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

  1. Jun 4, 20248-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights29
  2. May 31, 20248-K Other events30
  3. May 29, 20248-K Shareholder vote; Regulation FD disclosure31
  4. May 10, 20248-K Other events32
  5. May 7, 20248-K Results of operations33
  6. May 2, 20248-K Other events34
  7. Apr 23, 20248-K Other events35
  8. Apr 12, 20248-K Other events36
  9. Apr 9, 20248-K Other events37
  10. Mar 20, 20248-K Results of operations38
  11. Mar 19, 20248-K Entered a material agreement; Executive or director change; Bylaws or fiscal year changed39
  12. Feb 16, 20248-K Entered a material agreement; Regulation FD disclosure40
  13. Jun 25, 2020New chief executive John Valliant becomes CEO13
  14. 2020Went public Listed on NASDAQ1

Calendar

When it reported results

  1. May 7, 2024Reported quarterly or annual results33
  2. Mar 20, 2024Reported quarterly or annual results38
  3. Nov 7, 2023Reported quarterly or annual results41
  4. Aug 8, 2023Reported quarterly or annual results42
  5. May 11, 2023Reported quarterly or annual results43
  6. Mar 16, 2023Reported quarterly or annual results44
  7. Nov 8, 2022Reported quarterly or annual results45
  8. Aug 9, 2022Reported quarterly or annual results46

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

169 filings to the SEC since October 2021: 4 annual reports, 8 quarterly reports, 33 major events, 72 insider forms, 15 large holders, 37 other. The latest 20:

  1. Jun 17, 202415-12G EDGAR
  2. Jun 7, 2024EFFECT EDGAR
  3. Jun 7, 2024EFFECT EDGAR
  4. Jun 7, 2024EFFECT EDGAR
  5. Jun 4, 2024POS AM EDGAR
  6. Jun 4, 2024POS AM EDGAR
  7. Jun 4, 2024POS AM EDGAR
  8. Jun 4, 2024S-8 POS EDGAR
  9. Jun 4, 2024S-8 POS EDGAR
  10. Jun 4, 2024S-8 POS EDGAR
  11. Jun 4, 2024S-8 POS EDGAR
  12. Jun 4, 2024S-8 POS EDGAR
  13. Jun 4, 20248-K EDGAR
  14. Jun 4, 20244 EDGAR
  15. Jun 4, 20244 EDGAR
  16. Jun 4, 20244 EDGAR
  17. Jun 4, 20244 EDGAR
  18. Jun 4, 20244 EDGAR
  19. Jun 4, 20244 EDGAR
  20. Jun 4, 20244 EDGAR

The 169 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

46 open-market trades by officers, directors and large owners since October 2021: 1 buys and 45 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 11, 2022GANNON STEVENDirectorBuy44,400$2.03$90.1KForm 4
Apr 27, 2022Valliant JohnChief Executive OfficerSale4,511$6.03$27.2KForm 4
Apr 26, 2022Valliant JohnChief Executive OfficerSale2,147$6.07$13.0KForm 4
Apr 25, 2022Valliant JohnChief Executive OfficerSale2,036$6.03$12.3KForm 4
Apr 21, 2022Valliant JohnChief Executive OfficerSale922$6.01$5.5KForm 4
Apr 20, 2022Valliant JohnChief Executive OfficerSale367$6.02$2.2KForm 4
Apr 13, 2022Valliant JohnChief Executive OfficerSale11,994$6.41$76.9KForm 4
Apr 12, 2022Valliant JohnChief Executive OfficerSale18,255$7.10$129.6KForm 4
Apr 11, 2022Valliant JohnChief Executive OfficerSale2,600$7.37$19.2KForm 4
Apr 8, 2022Valliant JohnChief Executive OfficerSale826$7.52$6.2KForm 4
Apr 7, 2022Valliant JohnChief Executive OfficerSale1,255$7.56$9.5KForm 4
Apr 6, 2022Valliant JohnChief Executive OfficerSale100$7.58$758Form 4
Apr 5, 2022Valliant JohnChief Executive OfficerSale2,100$7.67$16.1KForm 4
Apr 4, 2022Valliant JohnChief Executive OfficerSale700$7.81$5.5KForm 4
Apr 1, 2022Valliant JohnChief Executive OfficerSale1,000$7.75$7.8KForm 4
Mar 30, 2022Valliant JohnChief Executive OfficerSale300$7.52$2.3KForm 4
Mar 29, 2022Valliant JohnChief Executive OfficerSale200$7.52$1.5KForm 4
Mar 28, 2022Valliant JohnChief Executive OfficerSale9,600$7.55$72.5KForm 4
Mar 25, 2022Valliant JohnChief Executive OfficerSale500$7.42$3.7KForm 4
Mar 23, 2022Valliant JohnChief Executive OfficerSale100$7.50$750Form 4

All 46 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Fusion Pharmaceuticals is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARFusion Pharmaceuticals Inc.2
  • CIK0001805890
  • Filer status<br>emerging growth company2
  • Incorporated inCanada (Federal Level)2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address270 Longwood Road South, Hamilton, A6 L8P 0A62
  • Phone289-799-08912
  • Shares outstanding85,059,965 as of Apr 29, 202412
  • Public float$302.2M as of Jun 30, 202356
  • On EDGAR sinceApr 3, 20202
  • Filings293 in all: 4 (108), 8-K (47), 3 (25), 10-Q (12), SC 13G (10), SC 13G/A (10), EFFECT (7), CORRESP (6)2
    All 37 form types

    DEFA14A (6), SC 13D/A (6), S-8 (5), S-8 POS (5), 10-K (4), SC 13D (4), UPLOAD (4), 8-K/A (3), DEF 14A (3), POS AM (3), S-3 (3), 144 (2), DRS/A (2), S-1/A (2), SEC STAFF LETTER (2), 10-K/A (1), 15-12G (1), 25-NSE (1), 424B4 (1), 424B5 (1), 8-A12B (1), ARS (1), CERT (1), DEFM14A (1), DFAN14A (1), DRS (1), DRSLTR (1), PREM14A (1), S-1 (1)

  • Latest filingsAnnual report (10-K) Mar 20, 2024
    Quarterly report (10-Q) May 7, 2024
    Proxy statement (DEF 14A) Apr 27, 2023
    Latest 8-K (8-K) Jun 4, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
    SEC EDGAROther events
  31. 31
  32. 32
    SEC EDGAROther events
  33. 33
  34. 34
    SEC EDGAROther events
  35. 35
    SEC EDGAROther events
  36. 36
    SEC EDGAROther events
  37. 37
    SEC EDGAROther events
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56